Type 2 diabetes manifests through entirely different biological mechanisms depending on a patient’s body mass index, according to research published in Diabetologia by Amsterdam UMC and the University of Ghana. While the condition in higher-BMI patients is driven primarily by insulin resistance, data from more than 3,300 African adults demonstrate that lower-BMI patients suffer from pancreatic failure to produce sufficient insulin. Despite these opposing physiological causes, medical guidelines currently prescribe identical treatments for both groups.
Divergent Disease Mechanisms Across Body Weight
The standard global view of type 2 diabetes links the condition primarily to excess body weight. In wealthy nations, roughly nine out of ten diagnosed individuals are overweight. However, data from the continent tell a starkly different story, according to first author Sabrina Esmail. Nearly four in ten African adults with type 2 diabetes present with a normal or low body weight, a figure that climbs to six in ten in rural areas such as Ghana.
“This means that there are an estimated ten million lean patients on the African continent who do not fit the standard picture,” Esmail stated. “For them, the problem is therefore a shortage of insulin, not a reduced response to insulin.” Project leader Charles Agyemang noted that the findings necessitate a search for better treatments tailored to this large demographic.
Clinical Mismatch in Standard Treatment Guidelines
Medical providers across Africa rely on international treatment guidelines that recommend oral tablets like metformin or sulfonylureas for all type 2 diabetes patients. Senior author Felix Chilunga explained that these pharmaceutical agents target insulin resistance rather than absolute insulin deficiency. Consequently, millions of lean patients likely receive ineffective care.
The researchers tracked distinct complication profiles between the cohorts. Lean patients developed eye damage, known as retinopathy, and strokes at higher rates. Overweight patients experienced higher blood pressure and an increased risk of cardiovascular disease more frequently. Chronic kidney disease affected both groups equally, according to the findings.
Did you know? Risk factors for the condition diverge sharply by weight class. While overweight diabetes is frequently tied to lifestyle factors, lean patients more often report histories of early malnutrition or low birth weight, which can impair pancreatic development.
Implications for African Populations in Europe
The treatment mismatch extends beyond the African continent. Analysis of data from the UK Biobank revealed that individuals of African descent with a BMI of 26 face the same diabetes risk as European populations with a BMI of 30. Research on migrant communities consistently shows that African patients develop type 2 diabetes roughly a decade earlier and experience poorer blood sugar control than native European populations.
“So a considerable proportion of African patients in Europe have a lower BMI but are treated according to guidelines written for the form of the disease found in people who are overweight, and their control is demonstrably worse,” Agyemang said. “There is no reason to assume that the treatment mismatch we describe stops at the border.”
Broader Vulnerabilities in Diabetes Risk Clusters
Additional research published in Diabetes by scientists from the German Center for Diabetes Research, University Hospital Tübingen, and Helmholtz Munich highlights that lifestyle interventions do not protect all patients equally. Investigators examining the Tübingen Lifestyle Intervention Program found that participants in high-risk cluster 5 experienced rising blood sugar, declining insulin secretion, and persistently elevated diabetes risk despite achieving and maintaining an 8% weight loss over nine years.
Lead author Professor Norbert Stefan reported that severe fatty liver disease and insulin resistance drove the persistent metabolic vulnerability in cluster 5. These physiological barriers impaired pancreatic beta cell function, suggesting that standard weight loss programs remain insufficient for patients with specific high-risk biological profiles.
Frequently Asked Questions
Why do lean Africans develop type 2 diabetes?
According to Amsterdam UMC and University of Ghana researchers, lean patients experience pancreatic failure to produce enough insulin rather than insulin resistance. This is often linked to early life malnutrition or low birth weight.
Are standard diabetes drugs effective for lean patients?
Medications like metformin primarily target insulin resistance. Researchers note that because lean patients suffer from an insulin shortage rather than resistance, these standard oral tablets are likely ineffective.
Do lifestyle changes prevent diabetes in everyone?
No. Research from the German Center for Diabetes Research shows that individuals in specific risk clusters, such as cluster 5, continue to experience rising blood sugar and declining insulin production despite sustained, long-term weight loss.